|
|
|
|
|
|
|
Free Newsletters
Archive
My Subscriptions
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers
Regional News
US & Canada
Biotech Bay
Biotech Beach
Genetown
Pharm Country
BioCapital
BioMidwest
Bio NC
BioForest
Southern Pharm
BioCanada East
US Device
Europe
Asia
Market Summary
News
IPOs
Company Profiles
Companies
Events
Research Store
Biotech Events
Post an Event
Real Estate
Business Opportunities
|
|
|
|
|
News | News By Subject | News by Disease |
News By Date | Search News
|
|
|
EMD Biosciences, Inc. And MorphoSys AG' Antibodies By Design Offer First Recombinant Antibody; For Detection Of Cyclophilin A, A Component Of Protein Folding
10/19/2005 5:12:17 PM
EMD Biosciences, Inc. (EMD Biosciences; www.emdbiosciences.com), a major supplier of premium tools for proteomics and disease pathway analysis known through its global brands Calbiochem(R), Novabiochem(R), and Novagen(R), today announced a unique addition to its catalog of research reagents: the first in vitro-derived, recombinant antibody (www.preview.emdbiosciences.com/product/ST1071). This antibody is targeted against human Cyclophilin A and is produced by MorphoSys' Antibodies by Design (www.a-by-d.com) division, a provider of rapid, high-throughput custom antibody reagent services for the academic and industrial research markets. EMD Biosciences is part of the Life Science and Analytics (LSA) division of Merck KGaA (Darmstadt, Germany; www.merck.de) and operates as EMD Biosciences, Inc. in North America and Merck Biosciences outside North America. Distribution of additional recombinant antibodies is planned under the collaboration. MorphoSys' Antibodies by Design division produces the antibodies using its HuCAL GOLD(R) library.
|
|
|
|
|
|
|
|
|
|
|